To determine if PCa HER2 surface expression is increased by a different method of quiescence induction, we used abemaciclib - an FDA-approved drug for the treatment of advanced or metastatic breast cancers, which selectively inhibits the cyclin dependent kinases CDK4/6 and promotes entry into G0 [22,23]. The gene discussed is CDK4; the disease is posterior cortical atrophy.